Literature DB >> 3343028

Experience with the Portacath.

M E Lambert1, G A Chadwick, A McMahon, J H Scarffe.   

Abstract

Fifty Portacaths have been inserted in patients undergoing prolonged outpatient chemotherapy, most for haematological disease. Twenty-one are still working at a median duration of 12 months (range 1-27) and a further 15 were functioning normally at the time of the patients death (median survival 6 months). Four functioning Portacaths have been removed, three suspected of causing septicaemia and one believed erroneously to have occluded. Ten have ceased to function and nine of these have been removed. The causes of these failures are nearly all avoidable and are discussed in detail; many occurred early in our experience. With careful attention to detail and with management by trained and interested staff, the Portacath is a safe and reliable device for intermittent vascular access.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3343028     DOI: 10.1002/hon.2900060109

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  2 in total

1.  Efficacy and clinical outcome of the port-a-cath in children: a tertiary care-center experience.

Authors:  Osama Bawazir; Elaf Banoon
Journal:  World J Surg Oncol       Date:  2020-06-19       Impact factor: 2.754

2.  Outcomes following port-a-catheter placement in the Medicare population.

Authors:  Syed I Khalid; Samantha Maasarani; Rachyl M Shanker; Aaron Lee Wiegmann; Rita Wu; Nicholas J Skertich; Samantha L Terranella; Laura DeCesare; Edie Y Chan
Journal:  Surg Open Sci       Date:  2020-11-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.